沙格列汀与二甲双胍联用覆盖T2DM多重病理生理缺陷,不仅降低糖尿病患者血糖,且不增加低血糖风险,兼减重效应。UKPDS研究证实,二甲双胍有心血管保护作用,SAVOR研究明确了沙格列汀的心血管安全性。国内即将上市的沙格列汀二甲双胍缓释片复方制剂可实现每日一次口服给药,提高患者依从性,带来更多的临床获益。依据国内外最新指南,该复方制剂可作为HbA_1c≥7.5%的新诊断T2DM患者,或二甲双胍单药治疗血糖未达标患者的治疗选择之一。 Saxagliptin and metformin combined with multiple pathophysiological defects covering T2DM, not only reduces blood glucose in diabetic patients, and does not increase the risk of hypoglycemia, and weight loss. UKPDS study confirmed that metformin has a cardiovascular protective effect, SAVOR study identified the cardiovascular safety of saxagliptin. The domestic upcoming saxagliptin metformin sustained-release tablets compound can be administered orally once daily to improve patient compliance and bring more clinical benefits. According to the latest guidelines both at home and abroad, the compound preparation can be used as one of the treatment options for newly diagnosed T2DM patients with HbA_1c ≥7.5%, or metformin monotherapy for patients with non-compliance blood glucose.